Procyon Advisors’s Moderna MRNA Stock Holding History

Procyon Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-625	Closed	-$241K	–	336
2021 Q3	$241K	Buy	+625	New	+$231K	0.06%	278

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Procyon Advisors's MRNA Position: Q4 2021 in Review

Procyon Advisors sold out of Moderna (MRNA) in Q4 2021, closing a stake of 625 shares — an estimated $241K sold.

Procyon Advisors first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $241K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Procyon Advisors reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Procyon Advisors sold 625 Moderna shares in Q4 2021, an estimated $241K.
Procyon Advisors first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Procyon Advisors's Moderna position peaked at $241K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Procyon Advisors's 13F filing for Q4 2021, filed 18 Jan 2022.